Stelfonta for Mast Cell Tumors in 2026: What We’ve Learned Over 5 Years

This lecture provides a practical, case-based update on the use of Stelfonta® for canine mast cell tumors, marking 5 years since FDA approval. Topics will include its unique mechanism of action, treatment administration, patient selection, and recent advances in cytologic grading. Drawing from more than 5 years of clinical experience, Dr Sue will share real-world insights on integrating Stelfonta® into practice, including how to identify appropriate candidates and manage expected tumor destruction and wound healing. The goal of this session is to give veterinarians practical guidance and greater confidence in using Stelfonta® as part of their treatment approach for canine mast cell tumors. 

• Review the practical and appropriate use of Stelfonta®, including case selection and tumor, patient, and client considerations
• Describe Stelfonta®’s unique mode of action and associated wound healing properties
• Identify factors critical to treatment success with Stelfonta®, including the role of concomitant medications
• To learn practical tips for using Stelfonta in everyday practice through case examples